Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.80.

A number of research firms have recently issued reports on RGLS. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th.

Regulus Therapeutics Stock Performance

RGLS opened at $1.64 on Friday. The company has a market capitalization of $107.42 million, a PE ratio of -1.53 and a beta of 1.63. The stock’s fifty day moving average is $1.53 and its 200-day moving average is $1.74. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RGLS. Barclays PLC increased its position in Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $46,000. State Street Corp increased its holdings in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 33,496 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Regulus Therapeutics during the third quarter valued at approximately $1,403,000. Finally, NEA Management Company LLC acquired a new stake in Regulus Therapeutics in the third quarter valued at approximately $10,154,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.